Acrongenomics, Inc. Announces Closing of $4,000,000 Private Placement to Fund Ongoing Operations
Acrongenomics, Inc. announced the closing of a 1,000,000 share private placement financing at $4.00 per share.
PR9.NET December 22, 2005 - Athens, Greece -- Acrongenomics, Inc. (OTCBB:AGNM) a publicly traded research and development nanobiotechnology company pioneering the development of uniquely advanced nano-molecular diagnostics, today announced the closing of the 1,000,000 share private placement financing at $4.00 per share as of Friday December 16th 2005. Acrongenomics will use the net proceeds for the ongoing development of the Nano-JETA platform as well as general corporate purposes.
"The success of this financing illustrates a strong confirmation of our approach, giving us the opportunity to focus on delivering advanced nanotechnology research to the life sciences industry. By putting together our scientific excellence and strong financial base, we have managed to complete this private placement financing earlier than expected," said Constantine Poulios, Acrongenomics' Vice President.
Acrongenomics also announces that it is proceeding to obtain an independent evaluation of its technology from a certified reference laboratory.
# # #
About Acrongenomics Inc.
Acrongenomics, Inc. (OTCBB: AGNM) is a research & development nanobiotechnology company pioneering the development of uniquely advanced nanomolecular diagnostics for the Life Sciences Industry. The Company seeks to establish its proprietary nanotechnology platform as a standard in Molecular In Vitro Diagnostics.
Acrongenomics Inc. is dedicated to transforming scientific concepts into reality, as it has successfully applied Nanotechnology inspirations into next-generation Biotechnology applications.
|Recent News Headlines
|Industry Category of Current Press Release